Considering these data and motivated by the positional isomerism strategy in generating new promising bioactive compounds, new derivatives of N5-substituted-pyrazolo[3,4-d]pyrimidinones were designed as antiproliferative CDK2 inhibitors against HCC and CRC. This evidence concerns the gene CDK2 and colorectal carcinoma.